Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden
- 30 November 2018
- journal article
- research article
- Published by Taylor & Francis in Infectious Diseases
- Vol. 51 (2) , 131-139
Abstract
Background: In both Russia and Sweden, the dominant hepatitis C virus (HCV) is genotype 1, but around one-third of patients have genotype 3 infection. For such countries, HCV genotype testing is recommended prior to therapy. An effective pangenotypic therapy may potentially eliminate the need for genotyping. In this study, we evaluated the efficacy and safety of sofosbuvir/velpatasvir for 12 weeks in patients from Russia and Sweden. Methods: In an open-label, single-arm phase-3 study, patients could have HCV genotype 1–6 infection and were treatment-naïve or interferon treatment-experienced. All patients received sofosbuvir/velpatasvir, once daily for 12 weeks. The primary endpoint was sustained virologic response 12 weeks post-treatment (SVR12). Results: Of 122 patients screened, 119 were enrolled and treated. Overall, half (50%) were male, 18% had cirrhosis, and 24% had failed prior interferon-based therapy. In total, 66% of patients were infected with HCV genotype 1 (59% 1b and 7% 1a), 6% with genotype 2, and 29% with genotype 3. The overall SVR12 rate was 99% (118/119, 95% confidence interval 95–100%). One treatment-experienced patient infected with HCV genotype 3 experienced virologic relapse after completing treatment. The most common adverse events were headache (16%) and fatigue (7%). Serious adverse events were observed in four patients, but none were related to treatment. No patients discontinued treatment due to adverse events. Conclusion: Sofosbuvir/velpatasvir as a pangenotypic treatment for 12 weeks was highly effective in patients from Russia and Sweden infected with HCV genotypes 1, 2, or 3. Sofosbuvir/velpatasvir was safe and well-tolerated. Clinical trial number: ClinicalTrials.gov NCT02722837.Keywords
Funding Information
- Gilead Sciences
- Gilead Sciences Inc.
This publication has 20 references indexed in Scilit:
- Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trialJournal of Hepatology, 2016
- Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in RussiaWorld Journal of Hepatology, 2016
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionNew England Journal of Medicine, 2015
- Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisNew England Journal of Medicine, 2015
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionNew England Journal of Medicine, 2015
- Efficacy of Sofosbuvir plus Ribavirin in Treatment-Naive Patients with Genotype-1 and -3 HCV Infection: Results from a Russian Phase IIIb StudyAntiviral Therapy, 2015
- The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2Journal of Viral Hepatitis, 2015
- Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysisAnnals of Hepatology, 2015
- The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategiesScandinavian Journal of Gastroenterology, 2014
- Patient adherence issues in the treatment of hepatitis CPatient Preference and Adherence, 2014